In one paragraphArticle in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 3 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
34 authors at 12 institutions in 6 countries.
Azlina Ahmad AnnuarDepartment of Biomedical Science, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.ORCID 0000-0002-9000-793X Soraya BardienDivision of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.ORCID 0000-0002-3508-3438 Melina EllisNorthcott Neuroscience Laboratory, ANZAC Research Institute, Concord, New South Wales, Australia.ORCID 0000-0002-8542-048X Thomas GasserDepartment for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.ORCID 0000-0002-1069-1146 Peter HeutinkDepartment for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.ORCID 0000-0001-5218-1737 Ignacio J Keller SarmientoKen and Ruth Davee Department of Neurology and Simpson Querrey Center for Neurogenetics, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA.ORCID 0000-0003-0979-6001 Shen-Yang LimDivision of Neurology, Department of Medicine, and the Mah Pooi Soo and Tan Chin Nam Centre for Parkinson's and Related Disorders, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.ORCID 0000-0002-6942-2522 Niccolò E MencacciKen and Ruth Davee Department of Neurology and Simpson Querrey Center for Neurogenetics, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA.ORCID 0000-0003-3383-9665 Mike A NallsDataTecnica, Washington DC, USA.
Shalini PadmanabhanDiscovery & Translational Research, The Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA.
J SolleDepartment of Clinical Research, Michael J. Fox Foundation for Parkinson's Research, New York City, NY, USA.ORCID 0000-0002-9941-4830 Ai-Huey TanDivision of Neurology, Department of Medicine, and the Mah Pooi Soo and Tan Chin Nam Centre for Parkinson's and Related Disorders, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.ORCID 0000-0002-2979-3839 Andrew SingletonCenter for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
Cornelis BlauwendraatCenter for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0001-9358-8111 Global Parkinson’s Genetics Program (GP2)
University of Lübeck · DEGerman Center for Neurodegenerative Diseases · DENational Institutes of Health · USUniversity of Malaya · MYUniversity of Pavia · ITMichael J. Fox Foundation · USNorthwestern University · USThe University of Sydney · AUUniversity Hospital Schleswig-Holstein · DECleveland Clinic · USSouth African Medical Research Council · ZAUniversity of the Free State · ZA
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Until recently, about three-quarters of all monogenic Parkinson's disease (PD) studies were performed in European/White ancestry, thereby severely limiting our insights into genotype-phenotype relationships at global scale. The first systematic approach to embrace monogenic PD worldwide, The Michael J. Fox Foundation Global Monogenic PD (MJFF GMPD) Project, contacted authors of publications reporting individuals carrying pathogenic variants in known PD-causing genes. In contrast, the Global Parkinson's Genetics Program's (GP2) Monogenic Network took a different approach by targeting PD centers not yet represented in the medical literature. Here, we describe combining both efforts in a "merger project" resulting in a global monogenic PD cohort with build-up of a sustainable infrastructure to identify the multi-ancestry spectrum of monogenic PD and enable studies of factors modifying penetrance and expression of monogenic PD. This effort demonstrates the value of future research based on team science approaches to generate comprehensive and globally relevant results.
Identifiers
PMID38529492
PMCPMC10962747
OpenAlexW4392864525
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390